• Hypercoagulability is a major contributor to COVID-19 related pulmonary complications; • Commonly used approaches may be insufficient to ameliorate the risk of thromboembolic events in patients with COVID-19; • Even when on thromboprophylaxis, it is crucial to remain vigilant for the occurrence of VTE in patients with COVID-19.